Revance Therapeutics. has filed a patent for a multi-tenant loyalty platform that allows for the selective configuration of loyalty programs in a multi-tenant environment. The platform includes interactive user interfaces that enable collaboration between tenants and the platform to configure and implement loyalty programs. The platform also includes features for calculating and comparing program outputs and reconfiguring programs for improved efficiency. GlobalData’s report on Revance Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Revance Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Revance Therapeutics's grant share as of September 2023 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
The patent filed is for a multi-tenant loyalty platform
A recently filed patent (Publication Number: US20230316322A1) describes a multi-tenant loyalty platform that allows for the selective configuration of loyalty programs in a multi-tenant environment. The platform includes a processor and memory storing instructions that configure the platform to perform various operations.
The first operation involves presenting loyalty program options to a first tenant in the multi-tenant environment through a user interface. The first tenant can then collaborate with the platform to configure the selected program options. The platform receives order data specific to the first tenant's loyalty program configuration and stores it in a loyalty program data structure. This process is repeated for a second tenant, with different order data specific to their loyalty program configuration.
Once the loyalty program data is stored, the platform configures and implements the loyalty programs for both tenants. It calculates outputs for each loyalty program and compares them based on a normalized or homogenized base construct. The platform then presents the outputs and comparison result to the respective tenants through a third interface. Based on the comparison result, the loyalty program can be reconfigured to improve efficiency.
The patent also describes a method for configuring a loyalty program using the multi-tenant loyalty platform. The method involves presenting loyalty program options to tenants, receiving order data specific to their program configurations, storing the data in a loyalty program data structure, configuring and implementing the loyalty programs, calculating outputs, comparing the outputs, and reconfiguring the program based on the comparison result. Additionally, the method includes calculating outputs based on user input during the checkout process and presenting them as rewards for specific purchases.
Overall, this patent introduces a multi-tenant loyalty platform that allows for the selective configuration of loyalty programs in a multi-tenant environment. It enables collaboration between the platform and tenants, provides a comparison of loyalty program outputs, and offers the ability to improve program efficiency based on the comparison result.
To know more about GlobalData’s detailed insights on Revance Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
